BioCryst Pharmaceuticals, Inc. announces transactions totaling 350 million USD in new funding, among other things supporting additional investment in the global launch of Orladeyo (berotralstat), which is on a trajectory to become the market-leading prophylactic HAE therapy.

“The focused execution of our plan this year, with the successful launch of Orladeyo, has led to further investment from exceptional and committed partners. The infusion of 350 million USD on top of our growing revenue base from Orladeyo enables us to invest now to maximize the value of among other products Orladeyo. We appreciate the confidence our partners are demonstrating in BioCryst with this financing as we continue to bring oral medicines to patients with rare diseases,” says Jon Stonehouse, CEO of BioCryst.
(Source: BioCryst)